APC anti-mouse CD279 (PD-1) Antibody
- 产品名称：
- APC anti-mouse CD279 (PD-1) Antibody
- 产品类别：
- 抗体
- 产品编号：
- 109111
- 产品应用：
- 109111
- Verified Reactivity
- Mouse
- Antibody Type
- Monoclonal
- Host Species
- Rat
- Immunogen
- Mouse PD-1 transfected BHK cells
- Formulation
- Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
- Preparation
- The antibody was purified by affinity chromatography and conjugated with APC under optimal conditions.
- Concentration
- 0.2 mg/ml
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
- Application
-
FC - Quality tested
- Recommended Usage
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 ?g per million cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.
- Excitation Laser
- Red Laser (633 nm)
- Application Notes
The RMP1-30 antibody does not block the binding of PD-1 to B7-H1 and B7-DC1.
- Application References
(PubMed link indicates BioLegend citation) -
- Matsumoto K, et al. 2004. J. Immunol. 172:2530.
- Raimondi G, et al. 2006. J. Immunol. 176:2808. (FC) PubMed
- King IL, et al. 2009. J. Exp Med 206:1001. (FC) PubMed
- Product Citations
-
- Perruzza L, et al. 2019. Sci Rep. 9:9315. PubMed
- Carlsson J, et al. 2015. PLoS One. 10: 0143741. PubMed
- Valencia–Hernandez AM, et al. 2020. Cell Host & Microbe. 27(6):950-962. PubMed
- Tatsuguchi T, et al. 2022. Int Immunol. 34:277. PubMed
- Manukian G, et al. 2021. Int J Radiat Oncol Biol Phys. 110:1341. PubMed
- Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
- Markov SD, et al. 2021. Mol Cancer Ther. 20:2457. PubMed
- Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed
- Davidson S, et al. 2020. Cell Reports. 31(7):107628. PubMed
- Shen Y, et al. 2022. CNS Neurosci Ther. 28:46. PubMed
- Lv Z, et al. 2020. Oncoimmunology. 9:1747688. PubMed
- Sekiya T, et al. 2015. J Exp Med. 212: 1623-1640. PubMed
- Chauveau L, et al. 2021. EMBO Rep. 22:e52447. PubMed
- Xing Y, et al. 2022. Cancer Lett. 529:100. PubMed
- Cedeno-Laurent F, et al. 2010. J Immunol. 185:4659. PubMed
- Zhao Y et al. 2018. Cell reports. 24(2):379-390 . PubMed
- Kato Y, et al. 2015. J Immunol. 195: 1006-1014. PubMed
- Lewis KE, et al. 2018. Oncoimmunology. 7:e1377873. PubMed
- Zhong M, et al. 2022. Cell Death Dis. 13:671. PubMed
- Wang X, et al. 2021. Theranostics. 11:209. PubMed
- Laczkó D, et al. 2020. Immunity. 53:724. PubMed
- RRID
- AB_10613470 (BioLegend Cat. No. 109111) AB_10612938 (BioLegend Cat. No. 109112)
- Structure
- Ig superfamily, 50-55 kD
- Distribution
-
Subset of double negative thymocytes, activated T and B cells
- Function
- Lymphocyte clonal selection, peripheral tolerance
- Ligand/Receptor
- PD-L1 (B7-H1), PD-L2
- Cell Type
- B cells, T cells, Thymocytes, Tregs
- Biology Area
- Apoptosis/Tumor Suppressors/Cell Death, Cancer Biomarkers, Cell Biology, Immunology, Inhibitory Molecules
- Molecular Family
- CD Molecules, Immune Checkpoint Receptors
- Antigen References
-
1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Agata Y, et al. 1996. Int. Immunol. 8:765.
3. Nishimura H, et al. 2001. Science 291:319.
4. Ishida Y, et al. 1992. EMBO J. 11:3887.
- Gene ID
- 18566 View all products for this Gene ID
- UniProt
- View information about CD279 on UniProt.org
